Six years is a long time to build the legal architecture for a biosimilar company that has now cleared five products across the U.S., Europe, and multiple emerging markets — and the departure of Alvotech’s General Counsel Tanya Zharov at this precise moment carries more strategic weight than a routine executive transition suggests.
Alvotech is not in build-mode anymore. The Iceland-headquartered company has spent the better part of a decade constructing its regulatory and commercial foundation: three public listings, a dense web of partnership agreements spanning Japan, China, South America, Africa, and the Middle East, and a pipeline of nine additional biosimilar candidates. That infrastructure is now largely in place. Zharov’s own framing — that she participated in the “build-up phase” — is the tell. The legal complexity ahead shifts from structuring to defending: patent litigation on adalimumab and ustekinumab biosimilars in the U.S. remains an ongoing cost center, and new entrants into denosumab and aflibercept markets will generate fresh IP skirmishes. Her successor, Lisa Graver, inherits a litigation and compliance posture, not a greenfield mandate.
The relocation detail deserves attention. Graver is relocating to Reykjavik, which Zharov explicitly did not do. For a company whose executive team is increasingly consolidating around its Icelandic headquarters, this signals a deliberate cultural and operational tightening under Chairman Róbert Wessman. Biosimilar margins are thin, coordination costs across a global commercial partnership network are not, and centralizing senior leadership reduces one variable. Zharov, meanwhile, moves to board-level roles at Wessman’s holding vehicles — Aztiq and Flóki — preserving the institutional knowledge within the broader network without it sitting on Alvotech’s payroll.
The Q1 2026 financial results, due imminently, will be the first earnings report under this new legal leadership configuration. Watch Alvotech’s U.S. revenue line specifically — adalimumab biosimilar share gains against AbbVie’s Humira and the early denosumab ramp are the clearest indicators of whether the commercial partnerships that Zharov helped negotiate are actually converting into durable market position, or whether the next General Counsel faces a renegotiation cycle before she’s fully settled in Reykjavik.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
